SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq:
VICL) today announced that Vical's President and Chief Executive Officer,
Vijay B. Samant, will provide an overview of the company's technologies,
development programs, and strategic partnerships at three upcoming investor
* Bank of America 2008 Health Care Conference (Las Vegas, May 13 - 15),
* FBR Capital Markets 12th Annual Spring Investor Conference
(New York, May 28-29),
* Needham & Company Seventh Annual Biotechnology and Medical Technology
A webcast of the presentation at the Needham conference will be available live and archived through the events page at http://www.vical.com.
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
Contact: Alan R. Engbring
|SOURCE Vical Incorporated|
Copyright©2008 PR Newswire.
All rights reserved